Home

Clients

Alseres Pharmaceuticals, Inc. is a biotechnology company engaged in the development of biopharmaceutical products for the treatment of traumatic injuries and degenerative diseases. The Company maintains a world-class position in the field of regenerative therapeutics. Our energy and focus are reflected in several important initiatives. The lead candidate, Cethrin®, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, has reported positive interim results in a Phase I/IIa clinical trial. Their molecular imaging program has a product candidate, ALTROPANE® molecular imaging agent, in Phase 3 clinical development. ALTROPANE® is a diagnostic tool intended to aid in differentiating Parkinsonian tremors from non-Parkinsonian or Essential Tremor. The Company's research and pre-clinical CNS programs include Inosine for the treatment of spinal cord injury and stroke, a DAT blocker for the treatment of Parkinson's disease, and a second generation technetium-based molecular imaging agent for PD and ADHD. Their sponsored scientific research in ground-breaking regenerative technologies may someday make possible other therapies for stroke, spinal cord and ocular injuries, bone repair and cardiovascular indications.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute.
Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders.
Javelin Pharmaceuticals together with its subsidiaries, engages in the research, development, and commercialization of products for pain relief in the United States. Its product candidates include Dyloject, which is in Phase III development stage for the treatment of post-operative pain in the United States, as well as in MAA Review stage for the treatment of acute forms of pain, including renal colic, exacerbations of osteo and rheumatoid arthritis, acute back pain, acute gout, acute trauma, and pain associated with fractures in Europe. The company's products also include Rylomine, an intranasal formulation of morphine that is in Phase III development stage for the treatment of acute moderate-to-severe pain and breakthrough pain in the United States and Europe; and PMI-150, a proprietary nasal formulation of ketamine that is under registration studies for the treatment of acute moderate-to-severe pain, including breakthrough pain in the United States. Its products also focus on treating various pain disorders, including episodic moderate-to-severe pain associated with breakthrough cancer pain; and post-trauma pain, such as orthopedic injury pain, procedural pain, and burn pain. The company was founded in 1998 and is based in Cambridge, Massachusetts.
Novelos Therapeutics is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of Cancer and Hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under a SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and an immunomodulator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer, and is in addition being developed for acute radiation injury. NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were originally developed.
QuantRx Biomedical is an emerging leader in the development of products for advanced diagnosis of serious disease and health conditions. With synergistic expertise in the discovery of diagnostic platforms and the commercialization of products for use by either medical professionals or consumers, QuantRx is focused on providing more accurate, reliable and faster diagnoses that result in improved patient care. The QuantRx strategy is one of sustained growth and targets significant market opportunities estimated to be in excess of $4 billion worldwide. The Company's technology portfolio, leveraging 15 patents and licenses, includes RapidSense® point-of-care testing products, based on QuantRx core intellectual property related to lateral flow techniques that rapidly provide medical information directly to the healthcare provider or patient. QuantRx affiliate FluoroPharma is developing important molecular imaging agents for positron emission tomography -- PET -- and fluorescence imaging, addressing significant unmet medical needs by providing clinicians with important tools for early discovery and assessment of disease. Initial application is in the treatment of cardiovascular disease. Other QuantRx technology platforms are genome-based diagnostic chips for the laboratory-based diagnostic market and PAD technology for diagnosis and treatment of women's health concerns and other medical needs.
Rival Technologies, Inc. is an innovative energy related technology company, investing in emerging technologies. Rival has filed several provisional patents and patent applications and is now focused on licensing its technology for industry use. Each technology benefits the environment, reduces global warming, and has exceptional market segment potential.
UTEK a leading, market-driven technology transfer company that enables companies of all sizes to acquire innovative technologies from universities and research laboratories worldwide. Our unique U2B process enables publicly traded firms in a wide range of industries to rapidly acquire university discoveries in exchange for their equity securities. Since its inception, UTEK has completed more than 55 technology transfers and currently owns stakes in approximately 50 publicly traded companies.
Xethanol seeks to become a leader in the emerging biomass-to-ethanol industry. Our mission is to convert biomass that is currently being abandoned or land filled into ethanol and other valuable co-products. Xethanol's strategy is to deploy proprietary bio-technologies that will extract and ferment the sugars trapped in these biomass concentrations. Xethanol's value proposition is to produce ethanol and valuable co-products more cost-effectively than corn-based processors with plants located closer to biomass sources.
Visual Management Systems Holding, Inc. provides business owners with loss prevention management solutions by implementing surveillance technologies that enable those owners to view their business live from anywhere in the world. VMS has established that there is an extremely active and aggressive market for loss prevention technology through the use of digital recording and video transmission to remote locations and corporate offices.
Yardville National Bank with a network of 28 conveniently located branches throughout New Jersey and eastern Pennsylvania, is a full service community bank committed to developing and enhancing lasting relationships with our customers. YNB has been an integral part of the community for over 80 years and we pride ourselves on products and services that are tailored to best meet the financial needs of individuals and businesses in our area. With this strong commitment to personalized service and community focused banking, YNB is proud to be Your Neighborhood Bank.